Pharmacokinetics of dalfampridine extended release 7.5‐mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open‐label study
Authors:
Open Access
- 30 September 2013
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (1) , 53-60
Abstract
Dalfampridine extended release tablets (D‐ER; prolonged‐release fampridine in Europe) are available to improve walking in patients with multiple sclerosis (MS). D‐ER is mainly renally eliminated; the approved 10‐mg twice daily dose is contraindicated in the United States in patients with moderate or severe renal impairment. This study evaluated single‐dose and steady‐state pharmacokinetics of a 7.5‐mg dose of D‐ER in healthy subjects (n = 13) and subjects with mild (n = 17) and moderate (n = 12) renal impairment. D‐ER plasma concentrations were consistently higher in subjects with renal impairment relative to healthy individuals with a significant (P < .0001) inverse linear relationship between creatinine clearance and drug exposure. Steady‐state AUC0–12 among healthy subjects, 167.0 ± 55.3 ng h/mL, increased 74% and 151% with mild and moderate renal impairment, respectively. The overall incidence of adverse events was 61.5%, 47.1%, and 33.3% in healthy subjects, and subjects with mild and moderate renal impairment, respectively, and for treatment‐related adverse events the rates were 0%, 17.6%, and 8.3%, respectively. The most common adverse events were headache, dizziness, and arthralgia. The pharmacokinetics of D‐ER 7.5‐mg twice daily in subjects with mild renal impairment was comparable to 10‐mg twice daily in patients with MS who had normal renal function. Exposure was significantly higher in moderate renal impairment.Keywords
This publication has 17 references indexed in Scilit:
- Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosisCurrent Medical Research and Opinion, 2011
- Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practiceTherapeutic Advances in Neurological Disorders, 2011
- Symptomatic Management in Multiple SclerosisNeurologic Clinics, 2011
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnnals of Neurology, 2010
- Single‐Dose Pharmacokinetics of Sustained‐Release Fampridine (Fampridine‐SR) in Healthy Volunteers and Adults With Renal ImpairmentThe Journal of Clinical Pharmacology, 2010
- Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individualsExpert Opinion on Investigational Drugs, 2009
- Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trialClinical Therapeutics, 2009
- Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up studyClinical Therapeutics, 2009
- Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteersClinical Therapeutics, 2009
- 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerveBrain Research, 1985